https://www.selleckchem.com/products/cpi-1205.html
Analysis by cumulative dose of metformin showed significantly lower mortality risk in the highest cumulative dose category (HR 0.76, 95% CI 0.58-0.99). Our study showed that metformin might have a survival benefit for pancreatic cancer patients, suggesting a potentially available option for the treatment. Our study showed that metformin might have a survival benefit for pancreatic cancer patients, suggesting a potentially available option for the treatment.Metal-binding inducible proteins called metallothioneins (MTs) protect cells fro
Like
Comment
Share
